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Abstract Prostaglandin H synthase (PHS) is a dual enzyme 
with cyclo-oxygenase and peroxidase activities. The nitric oxide 
(NO) donors, sodium nitroprusside (SNP), S-nitroso-A'-acetyl-
penicillamine (SNAP) and spermine NONOate (SPER/NO), 
activated both cyclo-oxygenase and peroxidase activities of 
PHS. SNP activated PHS by increasing Kmax without affecting 
Km, the activation constants being 1.0 mM for cyclo-oxygenase 
and 1.3 mM for peroxidase. Analysis of progress curves and 
absorption spectra of P H S suggested that N O released from 
S N P interacted with the heme at the active site of the enzyme. 
Moreover, SNP counteracted the peroxide-induced inactivation 
of PHS, suggesting that the interplay between the intracellular 
peroxide and N O is critical in tuning P H S activity in cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Arachidonic acid can be converted into prostanoids (i.e., 
prostaglandins, prostacyclin, thromboxane) or leukotrienes 
and lipoxins, all biologically active compounds, via the cy-
clo-oxygenase pathway or the lipoxygenase pathway (Scheme 
1). Prostaglandin H (prostaglandin endoperoxide) synthase 
(E.C. 1.14.99.1; PHS) is a heme-containing oxygenase which 
catalyses the first committed step in prostanoid formation [ 1 -
3]. PHS is a dual enzyme, because two catalytic activities co-
purify with a single protein molecule: cyclo-oxygenase and 
peroxidase. The cyclo-oxygenase activity catalyzes the addi-
tion of two molecules of oxygen to one molecule of arachi-
donic acid, thus forming a cyclic endoperoxide hydroperoxide, 
prostaglandin G2 (PGG 2 ) . The peroxidase activity reduces the 
hydroperoxide to the corresponding alcohol, prostaglandin 
H2 (PGH2), at the expense of a reducing co-substrate, D H . 
These reactions can be schematically represented as follows: 
Arachidoriicacid + 202—>PGG2 (cyclo—oxygenase) 
P G G 2 + 2 D H ^ P G H 2 + 2 D - + H 2 0 (peroxidase) 
Nitric oxide (NO) is a regulatory molecule involved in sev-
eral processes, as different as platelet aggregation and neuro-
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transmission [4,5]. Recently, we found that N O donors inhibit 
the lipoxygenase pathway of arachidonate cascade by acting 
as competitive inhibitors of enzyme activity [6]. Our results 
provided a biochemical background to the decrease of lipoxy-
genase metabolites observed in cells challenged with N O [7]. 
On the other hand, the effect of N O on PHS has been studied 
so far only in cellular systems and has led to conflicting re-
ports showing either activation [8-10] or inhibition [11-13] of 
cyclo-oxygenase activity. Therefore, the possible role of N O in 
modulat ing the cyclo-oxygenase pathway of arachidonate cas-
cade remains unclear. In this study, we used pure PHS to 
investigate the interaction of N O with both cyclo-oxygenase 
and peroxidase activities of the enzyme. Because peroxide 
tone is a critical factor in modulating PHS [14] and it can 
represent a constraint in prostaglandin biosynthesis in tissues 
[15], we studied the possible interplay between N O and per-
oxides in tuning P H S activity. Results presented in this paper 
help to clarify the overall picture of the role of N O in the 
control of arachidonate cascade, suggesting that nitric oxide 
inhibits the lipoxygenase [6,7] while activating the cyclo-oxy-
genase pathway. 
2. Materials and methods 
Chemicals were of the purest analytical grade. Arachidonic (eicosa-
tetraenoic) acid, hemin, hydrogen peroxide (30%, w/w), phenol, so-
dium nitroprusside (sodium nitroferricyanide, SNP) and N,N,N',N'-
tetramethyl-p-phenylenediamine (TMPD) were from Sigma Chemical 
Co. (St. Louis, MO, USA). S-Nitroso-A'-acetylpenicillamme (SNAP) 
was purchased from Research Biochemicals International (Natick, 
MA, USA). Spermine NONOate (SPER/NO, (Z)-l-{7V-[3-aminoprop-
yl]-/Y-[4-(3-aminopropylammonio)butyl]-amino}-diazen-l-ium-l,2-dio-
late) was from Alexis Corporation (Laufelfingen, Switzerland). 5-, 12-
and 15-Hydroperoxyeicosatetraenoic acids (5-, 12- and 15-HPETEs), 
a kind gift from Mr. Guus van Zadelhof (Bijvoet Center for Biomo-
lecular Research, Utrecht University, The Netherlands), were biosyn-
thesized by incubating arachidonic acid with 5-, 12- or 15-lipoxygen-
ase, respectively. HPETEs were extracted from reaction mixtures on 
octadecyl-SPE columns (Baker, Deventer, The Netherlands) and pu-
rified by RP-HPLC, performed on a Perkin Elmer 1022 LC Plus 
liquid chromatograph (Norwalk, CO, USA) as reported [16]. Prosta-
glandin H synthase (E.C. 1.14.99.1; PHS), purified from ram seminal 
vesicles, was purchased from ICN Biochemicals (Cleveland, OH, 
USA). The enzyme preparation was electrophoretically pure, migrat-
ing as a single band of 71 kDa in 12% SDS-PAGE. Pure PHS showed 
a cyclo-oxygenase activity of 37 nmol 02-min_1 and a peroxidase 
activity of 14 mU, assayed as described below. 
2.1. Cyclo-oxygenase assay 
PHS was assayed for cyclo-oxygenase activity at 30°C by means of 
a polarographic electrode [17]. The standard reaction mixture con-
tained 0.1 M potassium phosphate (pH 7.2), 1 mM phenol and var-
ious amounts (0-100 uM) of arachidonate. The reaction was started 
by adding 35 nM PHS. Cyclo-oxygenase activity was expressed as 
nmol O2 consumed per min. Progress curves of the oxygenation of 
75 U.M arachidonic acid by 35 nM PHS were recorded by following 
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polarographically the oxygen consumption. The lag phase of the cy-
clo-oxygenase reaction (i.e., the time required to reach maximal veloc-
ity) was determined from the chart record tracing of oxygen consump-
tion versus time [18]. 
2.2. Peroxidase assay 
PHS was assayed for peroxidase activity at 30°C spectrophotomet-
rically, as described [19]. The reaction mixture consisted of 0.1 M 
Tris-HCl (pH 8.1), 170 uM TMPD, 1 uM hemin and various amounts 
(0-100 uM) of arachidonate. Reaction was started by addition of 35 
nM PHS. After 5 min incubation at 30°C, absorbance values at 590 
nm were measured, defining one unit (U) of peroxidase activity as the 
amount of PHS necessary to generate a change of 1 A590 unit during 
the 5 min incubation [19]. 
2.3. Kinetic analysis 
The effect of SNP on the cyclo-oxygenase and peroxidase activities 
of PHS was analysed by double reciprocal plots, using two different 
concentrations of freshly prepared NO donor (0.75 mM and 1.50 
mM) to calculate the kinetic parameters of each enzymatic activity. 
Fitting of the experimental points by a linear regression programme 
(Kaleidagraph) yielded straight lines with r-values > 0.93. 
2.4. PHS inactivation by peroxides 
The ability of peroxides to inactivate the cyclo-oxygenase and per-
oxidase activities of PHS was determined by pre-incubating 35 nM 
PHS with various amounts (0-1.0 uM) of each peroxide (H202, 5-, 
12- or 15-HPETEs) for 2 min at room temperature [14]. Enzyme 
activity was then measured using 75 uM arachidonate as substrate, 
in the presence or absence of freshly prepared SNP (0.50 mM) in the 
reaction mixture. 
2.5. Absorption spectra of PHS 
Absorption spectra of PHS were recorded in the wavelength range 
320-620 nm using 14 uM PHS in 0.1 M Tris-HCl (pH 8.1) [20]. The 
effect of NO on PHS spectral properties was investigated by adding 
freshly prepared SNP up to 200 mM. Absorption spectra were re-
corded at room temperature in a UV/VIS spectrometer Lambda 18 
(Perkin Elmer, Norwalk, CO, USA). 
2.6. Data analysis 
Data reported in this paper are the mean (±S.D.) of at least 
3 independent determinations, each performed in duplicate. Reported 
drawings are also representative of triplicate experiments. Statistical 
analysis was performed by the Student Mest, considering significant 
the difference between control and each treatment at least at 5% level 
(P<0.05). 
3. Results and discussion 
Prostaglandin H (prostaglandin endoperoxide) synthase 
(PHS) is a dual enzyme, which catalyzes the cyclo-oxygenase 
and peroxidase reactions leading to prostaglandms, prostacy-
clm and thromboxane synthesis from arachidonic acid [1-3]. 
The cyclo-oxygenase and peroxidase active sites, though resid-
ing on a single protein, are distinct [21]. Nevertheless, both 
activities of PHS were similarly enhanced by different NO 
donors in a dose-dependent manner (Fig. 1). SNP, SNAP 
and SPER/NO are structurally dissimilar compounds which 
share only the ability of releasing nitric oxide in aqueous 
solutions [22]. The different NO donors affected PHS activity 
in a similar manner (Fig. 1), suggesting that they acted by 
providing NO rather than directly. The release of NO from 
these widely used NO donors has been investigated [6,22,23], 
showing that millimolar concentrations of NO donors release 
free nitric oxide at concentrations in the physiological range 
and that free NO is no longer detectable in 12-h-old solutions 
of SNP, SNAP or SPER/NO. Interestingly, 12-h-old solutions 
ARACHIDONIC ACID 
PROSTAGLANDINS PROSTACYCLIN THROMBOXANE 1 2-HPETE 
LEUKOTRIENES 
1 5-HPETE 
LIPOXINS 
( CYCLOOXYGENASE PATHWAY ) ( LIPOXYGENASE PATHWAY ) 
Scheme 1. Arachidonic (eicosatetraenoic) acid metabolism is directed towards prostanoids (i.e., prostaglandms, prostacyclin and thromboxane) 
or leukotrienes and lipoxins (through hydroperoxyeicosatetraenoic acid (HPETE) intermediates). Biosynthesis of prostanoids is catalyzed by 
prostaglandin H synthase (PHS), via the so-called 'cyclo-oxygenase pathway'. Lipoxygenase (LOX) synthesizes leukotrienes and lipoxins in the 
so-called 'lipoxygenase pathway'. Nitric oxide (NO) inhibits (—) the lipoxygenase while activating (+) the cyclo-oxygenase pathway. 
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of all NO donors lost their ability to activate PHS (data not 
shown), corroborating the hypothesis that SNP, SNAP and 
SPER/NO were acting on PHS by releasing NO. SNP was 
slightly more efficient than SNAP or SPER/NO in activating 
PHS; therefore the effect of NO on PHS was further charac-
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Fig. 1. Effect of SNP (A), SNAP (B) and SPEPJNO (C) on the cy-
clo-oxygenase (open bars) and peroxidase (hatched bars) activities 
of PHS. Both PHS activities were measured using 75 uM arachido-
nate as substrate, 100% corresponding to 37 nmol (Vmin-1 and 14 
mU, respectively, for the cyclo-oxygenase and the peroxidase activ-
ity. Data are reported ±S.D. values (n = 6). *P<0.01 compared to 
control. **.P<0.05 compared to control. 
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Fig. 2. Double reciprocal plots of the cyclo-oxygenase (A) and per-
oxidase (B) activity of PHS, in the absence (circles) or presence of 
0.75 mM SNP (triangles) or 1.50 mM SNP (squares). Data are re-
ported ± S.D. values (n = 8). 
terized using SNP. Double reciprocal plots of cyclo-oxygenase 
and peroxidase activities of PHS were drawn, in the presence 
or absence of SNP (Fig. 2). From these plots the Kmax and Km 
values of the PHS reaction with arachidonate were calculated, 
and were 44.2 ±4.4 nmol 02-min
_1 and 14.1 ± 1.4 uM for the 
cyclo-oxygenase, 22.2 ± 2.0 mU and 36.7 ± 3.5 uM for the per-
oxidase. The double reciprocal plots showed SNP to activate 
PHS by increasing apparent Vmax without affecting Km values 
(Fig. 2). Therefore, the activation constant (K^) was calculated 
from the apparent Vmax in the presence of SNP (VmaxAPP), 
using the formula: 
^max,app — ^m s( i + [SNP]/^a; 
The K& values of SNP for the cyclo-oxygenase and the perox-
idase activities were 1.0 ±0.1 and 1.3 ±0.1 mM, respectively. 
We have recently measured the amount of NO released from 
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Fig. 3. Progress curves of the cyclo-oxygenase reaction using 75 uM arachidonate as substrate, in the absence (a) or presence of 0.75 mM SNP 
(b) or 1.50 mM SNP (c). Inset: Lag phase of the cyclo-oxygenase reaction. 
SNP in aqueous solutions [6]. Based on the release of nitric 
oxide from SNP, it was possible to estimate that K& values of 
NO for PHS were approximately 0.65 |iM for cyclo-oxygenase 
and 0.85 uM for peroxidase, respectively. The observation 
that SNP modulates in a similar way both activities of PHS 
is in keeping with the intimate correlation between these ac-
tivities in prostanoid biosynthesis. In order to characterize in 
more detail the activation of PHS by SNP, progress curves of 
the cyclo-oxygenase activity were recorded (Fig. 3). It is 
shown that SNP reduced the lag phase of the reaction (Fig. 
3, inset) in a dose-dependent manner, from approximately 8 s 
of the untreated control to approximately 4 s of the samples 
treated with 1.50 mM SNP. PHS is a heme-protein which 
requires ferriprotoporphyrin IX for both cyclo-oxygenase 
and peroxidase activities [1-3,14]. NO can bind to ferrous 
complexes and assist the oxidation of iron from ferrous to 
ferric form [24]. Indeed, the ability of NO to activate ferrous 
enzymes by oxidizing them to ferric forms has been reported 
[25,26]. Therefore, the shortening of the reaction lag phase 
might be indicative of a direct oxidation of inactive Fe(II) 
to active Fe(III) in the heme moiety. Also the analysis of 
the absorption spectra of PHS favours the hypothesis of a 
direct interaction of NO with heme. In Fig. 4 it is shown 
that addition of SNP increased the absorption of PHS in 
the region around 400 nm, where the spectrum is mainly con-
tributed by the heme moiety [20,24]. These spectral changes 
might be assigned to the formation of NO adducts such as 
iron-nitrosyl complexes, which have indeed been observed by 
EPR spectroscopy in PHS treated with gaseous NO [20]. On 
the other hand, cyclo-oxygenase and peroxidase activities of 
PHS are inactivated by pre-incubation with hydrogen perox-
ide (Fig. 5A,B). The peroxide-induced inactivation of cyclo-
oxygenase was paralleled by an increase in the lag phase of 
the reaction (Fig. 5C). The interaction of peroxides with PHS 
is known to generate higher oxidation states of the heme iron, 
such as Fe(IV) and Fe(V), which can undergo internal re-
arrangements or side-reactions, ultimately leading to enzyme 
inactivation [14,15,27]. Interestingly, the effect of H2O2 was 
prevented by SNP (Fig. 5). In particular, 0.5 mM SNP, which 
released 0.4 u,M NO in the buffer [6], fully counteracted the 
inactivation of PHS caused by 0.4 u,M hydrogen peroxide. 
Also the lag phase of the cyclo-oxygenase reaction returned 
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Fig. 4. Absorption spectra of 14 uM PHS in the absence (a) or presence (b) of 200 mM SNP. Inset: Difference spectrum calculated by sub-
tracting spectrum (a) from (b). 
to the control value when 0.5 mM SNP was added to the 
H202-treated enzyme (Fig. 5). Thus, it can be proposed that 
nitric oxide, which can behave also as a reducing agent [28], 
counteracts H2O2 by reducing Fe(IV) or Fe(V) to active 
Fe(III). NO might also protect PHS from peroxide inactiva-
tion by supporting peroxide reduction, which has been shown 
to occur when PHS is incubated with reducing substrates [14]. 
Interestingly, lipoxygenase-derived hydroperoxides 5- and 12-
HPETEs were more effective than H2O2 in inactivating PHS, 
whereas 15-HPETE was less effective (Table 1). SNP also 
counteracted the effect of these hydroperoxides, though to a 
different extent (Table 1). The potency of HPETEs in inacti-
vating PHS might correlate with the tridimensional structure 
of the active site, although more structural data are needed 
Table 1 
Inactivation of PHS by lipoxygenase products 
Peroxide Cyclo-oxygenase activity of PHS (nmol CVmin-1) 
- S N P +SNP 
Peroxidase activity of PHS (mU) 
- S N P +SNP 
None 
5-HPETE 
12-HPETE 
15-HPETE 
H 2 0 2 
37.0±3.5 
(100%) 
13.611.2 
(37%)* 
16.311.5 
(44%)* 
25.212.5 
(68%)** 
19.211.8 
(52%)* 
44.014.2 
(100%) 
33.413.2 
(76%)** 
34.813.5 
(79%)** 
46.614.5 
(106%) 
35.013.3 
(79%)** 
14.011.3 
(100%) 
4.610.5 
(33%)* 
5.510.5 
(39%)* 
10.111.0 
(72%)** 
6.410.6 
(46%)* 
16.711.6 
(100%) 
11.711.2 
(70%)** 
10.911.1 
(65%)* 
19.211.9 
(115%) 
15.011.5 
(90%) 
Hydroperoxy derivatives of arachidonic acid (HPETEs) were used at a final concentration of 0.4 uM in the presence or absence of 0.50 mM SNP. 
The effect of HPETEs was compared to that obtained with 0.4 |iM H2O2 (data from Fig. 5). Data 1 S.D. are reported (n = 8) and values in 
brackets represent percentages of the controls, arbitrarily set to 100. 
*P<0.01 compared to control. **P<0.05 compared to control. 
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Fig. 5. Inactivation of the cyclo-oxygenase (A) and peroxidase (B) 
activities of PHS by H2O2, and effect of H2O2 on the lag phase of 
the cyclo-oxygenase reaction (C). Measurements were performed in 
the absence (open bars) or presence (hatched bars) of 0.50 mM 
SNP, using 75 uM arachidonate as substrate. Data are reported 
±S.D. values (rc = 6). *P<0.01 compared to control. **P<0.05 
compared to control. 
for making more conclusive statements [29]. It is noteworthy 
that the effect of hydroperoxides on P H S occurs at micromo-
lar concentrations, which are in the physiological range [18]. 
This points out the key-role of the intracellular peroxide level 
in tuning the cyclo-oxygenase and peroxidase activities of 
PHS in the presence of N O [15,30]. Difference in peroxide 
levels might reconcile conflicting reports describing the ability 
of N O to activate [8-10] or inhibit [11-13] P H S in cellular 
extracts. Finally, it seems interesting that concentrations of 
SNP shown here to activate PHS have been reported to in-
hibit lipoxygenase activity, with an inhibition constant (Aj) of 
N O for lipoxygenase of 0.4 u M [6]. Therefore, it is tempting 
to suggest that nitric oxide modulates the arachidonate cas-
cade by inhibiting one branch (i.e., the lipoxygenase pathway) 
while activating the other (i.e., the cyclo-oxygenase pathway) 
at the same time (Scheme 1). Inhibition of lipoxygenase activ-
ity reduces the intracellular amount of HPETEs , thus increas-
ing the stimulatory effect of N O on PHS. Altogether, these 
findings might be relevant in (patho)physiological processes 
such as inflammation, neurotransmission, neurotoxicity and 
cell death [5,6,31-35], where nitric oxide could play its role 
by deranging the arachidonate cascade in favour of prosta-
noids. 
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